3.4.22.69 (-)-epigallocatechin-3-gallate remarkable inhibitory activity against SARS-CoV-2 3CLpro. In molecular docking, (-)-Epigallocatechin-3-gallatestrongly interacts with the substrate binding pocket of SARS-CoV-2 3CLpro, forming hydrogen bonds with catalytic residues C145 and H41 2518 3.4.22.69 (2E)-1-[3-(2-hydroperoxy-3-methylbut-3-en-1-yl)-2-hydroxy-4-methoxyphenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one - 239271 3.4.22.69 (2E)-N-[2-[4-(dimethylamino)butyl]phenyl]-3-phenylprop-2-enamide - 200832 3.4.22.69 (2S)-2-(8[(1R,3S,4aR,8aS)-1-[[butyl(methyl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239275 3.4.22.69 (2S)-2-([(1R,3R,4aR,8aS)-1-8[butyl(methyl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239274 3.4.22.69 (2S)-2-([[(1S,3R,4aR,8aS)-1-[[butyl(methyl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239272 3.4.22.69 (2S)-2-([[(1S,3S,4aR,8aS)-1[butyl(methyl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methylamino)-3-(1H-imidazol-4-yl)propanal - 239273 3.4.22.69 (2S)-2-([[(1S,4aR,8aS)-1-[[benzyl(methyl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239278 3.4.22.69 (2S)-2-([[(1S,4aR,8aS)-1-[[butyl(methyl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239276 3.4.22.69 (2S)-2-([[(3R,4aS,8aR)-2-(4-bromobenzoyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239282 3.4.22.69 (2S)-2-([[(3R,4aS,8aR)-2-(4-fluorophenyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-5-yl)propanal - 235472 3.4.22.69 (2S)-2-([[(3R,4aS,8aR)-2-([1,1'-biphenyl]-4-carbonyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239283 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-(4-bromobenzoyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239279 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-(4-bromobenzoyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-5-yl)propanal - 235473 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-(4-fluorobenzoyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239287 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-(biphenyl-4-ylcarbonyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-5-yl)propanal - 235474 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-([1,1'-biphenyl]-2-carbonyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239285 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-([1,1'-biphenyl]-3-carbonyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239284 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-([1,1'-biphenyl]-4-carbonyl)decahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239280 3.4.22.69 (2S)-2-([[(3S,4aR,8aS)-2-benzoyldecahydroisoquinolin-3-yl]methyl]amino)-3-(1H-imidazol-4-yl)propanal - 239286 3.4.22.69 (2S)-3-(1H-imidazol-4-yl)-2-([[(1S,4aR,8aS)-1-[[methyl(prop-2-en-1-yl)amino]methyl]octahydro-1H-2-benzopyran-3-yl]methyl]amino)propanal - 239277 3.4.22.69 (3E,5E)-3-[(3,4-dibromophenyl)methylidene]-5-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-1-methylpiperidin-4-one binding affinity -9.5 kcal/mol, binding free energy -223.0 kcal/mol 260762 3.4.22.69 (3E,5E)-3-[(3,4-dichlorophenyl)methylidene]-5-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-1-methylpiperidin-4-one binding affinity -9.6 kcal/mol, binding free energy -217.1 kcal/mol 260763 3.4.22.69 (3E,5E)-3-[(3,4-difluorophenyl)methylidene]-5-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-1-methylpiperidin-4-one binding affinity -9.6 kcal/mol, binding free energy -197.9 kcal/mol 260764 3.4.22.69 (3E,5E)-3-[(3,4-dihydroxyhenyl)methylidene]-5-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-1-methylpiperidin-4-one binding free energy -228.5 260765 3.4.22.69 (3E,5E)-3-[(4-fluorophenyl)methylidene]-5-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-1-methylpiperidin-4-one binding affinity -9.5 kcal/mol, binding free energy -194.1 kcal/mol 260766 3.4.22.69 (4E)-1,7-bis(3,4-dihydroxyphenyl)hept-4-en-3-one - 200921 3.4.22.69 (4Z)-4-[[4-(dimethylamino)phenyl]methylidene]-1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-one binding free energy -98.76 kJ/mol, compound shows favorable pharmacokinetic and drug-like properties 260810 3.4.22.69 (5S,8S,11S,E)-methyl 8-isobutyl-5-isopropyl-3,6,9-trioxo-11-(((S)-2-oxopyrrolidin-3-yl)methyl)-1-phenyl-2-oxa-4,7,10-triazatetradec-12-en-14-oate - 200876 3.4.22.69 (8E,11E,14E)-eicosa-8,11,14-trienoic acid methylester high binding energy of -129.673 kcal/mol 262536 3.4.22.69 (R)-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(3-methylpyrrolidin-1-yl)ethoxy)phenyl)methanone binding energy -66.7 kJ/mol 260864 3.4.22.69 (R)-N-(E)-3',4',5'-trimethoxy-3-phenylprop-2-enoicserine(benzoyl)cyclohexylamide IC50 value 0.5 mM for cathepsin B, not cytotoxic 235728 3.4.22.69 (R)-N-cinnamoyl serine(benzoyl)cyclohexylamide not inhibitory to cathepsin B at 1 mM, not cytotoxic 235729 3.4.22.69 (S)-2-((((1S,3R,4aR,8aS)-1-((butyl(methyl)amino)methyl)octahydro-1H-isochromen-3-yl)methyl)amino)-3-(1H-imidazol-4-yl)propanal - 239904 3.4.22.69 (S)-2-((2S,3R)-2-((S)-2-acetamido-3-methylbutanamido)-3-(benzyloxy)butanamido)-4-methyl-N-((S)-4-(5-nitro-1,4-dioxo-3,4-dihydrophthalazin-2(1H)-yl)-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)pentanamide - 65254 3.4.22.69 (S)-2-[([(3R,4aS,8aR)-2-[3-(phenylamino)-propan-1-carbonyl]decahydroisoquinolin-3-yl]methyl)amino]-3-(1H-imidazol-4-yl)-propanal - 235746 3.4.22.69 (S)-2-[([(3S,4aR,8aS)-2-[3-(phenylamino)-propan-1-carbonyl]decahydroisoquinolin-3-yl]methyl)amino]-3-(1H-imidazol-4-yl)-propanal - 235747 3.4.22.69 (S)-N-((S)-1-(((S)-1-(1H-imidazol-4-yl)-3-oxopropan-2-yl)amino)-3-cyclohexyl-1-oxopropan-2-yl)-2-((S)-2-((S)-2-acetamido-3-hydroxypropanamido)propanamido)-3-methylbutanamide - 200878 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((E)-3-(3,4-dimethoxyphenyl)acrylamido)-4-methylpentanamide - 200904 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((E)-3-(4-methoxyphenyl)acrylamido)-4-methylpentanamide - 200903 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((S)-2-(2-(3-(dimethylamino)phenoxy)acetamido)-3-methylbutanamido)-4-methylpentanamide - 200881 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-((2-methoxyphenyl)amino)acetamido)-4-methylpentanamide - 200911 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-((3-methoxyphenyl)amino)acetamido)-4-methylpentanamide - 200910 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-((4-methoxyphenyl)amino)acetamido)-4-methylpentanamide - 200909 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-(3-(dimethylamino)phenoxy)acetamido)-4-methylpentanamide - 200908 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-(4-hydroxyphenoxy)acetamido)-4-methylpentanamide - 200907 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-(4-methoxyphenyl)acetamido)-4-methylpentanamide - 200899 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(3-(4-methoxyphenyl)propanamido)-4-methylpentanamide - 200900 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-cinnamamido-4-methylpentanamide - 200902 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-4-methyl-2-((S)-3-methyl-2-(2-phenoxyacetamido)butanamido)pentanamide - 200880 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-4-methyl-2-(2-phenoxyacetamido)pentanamide - 200905 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-4-methyl-2-(2-phenylacetamido)pentanamide - 200898 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-4-methyl-2-(3-(pyridin-3-yl)propanamido)pentanamide - 200901 3.4.22.69 (S)-N-((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-4-methyl-2-(3-methylbutanamido)pentanamide - 200890 3.4.22.69 (S)-N-((S)-1-(bnzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-(2-(4-methoxyphenoxy)acetamido)-4-methylpentanamide - 200906 3.4.22.69 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[[3,1]benzoxazine-4,4'-piperidin]-2(1H)-one interacts with allosteric site I, binding free energy -15.3 kcal/mol, shows antiviral activity 260892 3.4.22.69 1,1'-sulfonylbis(4-nitrobenzene) - 65289 3.4.22.69 1,2,3,4,6-pentagalloylglucose remarkable inhibitory activity against SARS-CoV-2 3CLpro. In molecular docking, 1,2,3,4,6-pentagalloylglucose strongly interacts with the substrate binding pocket of SARS-CoV-2 3CLpro, forming hydrogen bonds with catalytic residues C145 and H41 262541 3.4.22.69 1,6-di(propan-2-yl)-N-(4-[[4-(prop-2-en-1-yl)-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl]methyl]-1,3-thiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide - 235788 3.4.22.69 1-(1-benzothiophen-2-ylmethyl)-5-iodo-1H-indole-2,3-dione - 24833 3.4.22.69 1-(2-naphthylmethyl)-2,3-dioxoindoline-5-carboxamide - 65303 3.4.22.69 1-(2-naphthylmethyl)isatin-5-carboxamide - 81315 3.4.22.69 1-(4-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one in the binding pose, the 1,4-dimethylpiperazine fragment has only pi-sulfur interaction with Met165, the pyrrolo[2,3-b] pyridine fragment of the inhibitor is in van der Waals and amino-pi interactions with Asn142, van der Waals interaction with Glu166, and has polar-pi interaction with Ser144 and cation-pi interactions with His163 262532 3.4.22.69 1-(naphthalen-2-ylmethyl)-2,3-dioxo-2,3-dihydro-1H-indole-5-carboxamide - 200885 3.4.22.69 1-butyl-N-[4-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzyl]-1H-benzimidazol-2-amine - 70026 3.4.22.69 1-hydroxypyridine-2-thione zinc - 66569 3.4.22.69 1-[(1H-benzimidazol-5-ylcarbonyl)oxy]-1H-1,2,3-benzotriazole inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65328 3.4.22.69 1-[(1H-indol-2-ylcarbonyl)oxy]-1H-1,2,3-benzotriazole inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65329 3.4.22.69 1-[(1H-indol-5-ylcarbonyl)oxy]-1H-1,2,3-benzotriazole inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65330 3.4.22.69 1-[(1H-indol-5-ylcarbonyl)oxy]-1H-benzotriazole - 69958 3.4.22.69 1-[(4-chlorophenyl)sulfonyl]-2-nitro-4-(trifluoromethyl)benzene - 65333 3.4.22.69 1-[2-(dimethylamino)ethyl]-3-hydroxy-5-(4-hydroxy-3-methoxyphenyl)-4-[2-methyl-4-(2-methylpropoxy)benzoyl]-1,5-dihydro-2H-pyrrol-2-one competitive inhibitor, 61.36% inhibition at 0.1 mM 86675 3.4.22.69 1-[bis(4-chlorophenyl)methyl]-3-[2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazol-3-ium - 65345 3.4.22.69 1-[[(2R)-oxiran-2-yl]methyl]-3,5-bis[[(2S)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione interacts with substrate-bindung site, binding free energy -20.7 kcal/mol, shows antiviral activity 261006 3.4.22.69 1-[[(5-fluoro-1H-indol-2-yl)carbonyl]oxy]-1H-1,2,3-benzotriazole inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65334 3.4.22.69 10a,11-dihydro-5aH-[1]benzofuro[3,2-b][1]benzopyran binding energy -114.3 kJ/mol, in-silico ADMET study displays excellent druggability and extremely low level of toxicity of the synthesized molecules 261012 3.4.22.69 2',4'-bis(benzyloxy)-3,5-dimethyl-4-hydroxy-trans-chalcone binding energy -87.9 kJ/mol 261016 3.4.22.69 2',5'-dimethyl-3-(methylthio)-4'-nitro-5-(2-thienyl)-2'H-1,3'-bipyrazole-4-carbonitrile - 65358 3.4.22.69 2,2-difluoro-2-(pyridin-3-yl)-1-(thiophen-2-yl)ethanone 0.1 mM, 38% inhibition 147287 3.4.22.69 2,4-diacetylphloroglucinol docking score -4.94 kcal/mol, interacts with residues GLU166, HIS164, ARG188, MET165, HIS41 206963 3.4.22.69 2,4-dichloro-5-methylphenyl 2,6-dinitro-4-(trifluoromethyl)phenyl sulfone - 65360 3.4.22.69 2,5-bis[[(benzyloxy)carbonyl]amino]-1,2,5,6-tetradeoxy-1,6-di-1H-indol-3-yl-L-iditol - 65361 3.4.22.69 2-(1H-benzotriazol-1-yl)-1-(1H-indol-5-yl)ethanone - 200886 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-(biphenyl-4-yl)-N-(thiophen-3-ylmethyl)acetamide - 200868 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-N-[4-[(methylsulfonyl)amino]phenyl]acetamide - 200840 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(1H-imidazol-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide - 261032 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(1H-imidazol-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0017 microM 261032 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(1H-pyrazol-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide - 261033 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(1H-pyrazol-4-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0058 microM 261033 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(benzylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide - 200867 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(methylamino)phenyl]-N-(thiophen-3-ylmethyl)acetamide - 200866 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(pyridin-3-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide - 200869 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(pyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide - 261034 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(pyridin-3-yl)phenyl]-N-[(thiophen-3-yl)methyl]acetamide cytopathic effect inhibition assay, EC50 value 0.012 microM 261034 3.4.22.69 2-(1H-benzotriazol-1-yl)-N-[4-(pyridin-4-yl)phenyl]-N-(thiophen-3-ylmethyl)acetamide - 200871 3.4.22.69 2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)-N-[4-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]acetamide - 261035 3.4.22.69 2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)-N-[4-(2-oxo-1,2-dihydropyridin-3-yl)phenyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0088 microM 261035 3.4.22.69 2-(3',4'-dihydroxyphenyl)-3-beta-D-galactosyl-4H-chromen-4-one 0.05 mM, 30.1% inhibition 139119 3.4.22.69 2-(3',4'-dihydroxyphenyl)-5,7-dihydroxy-3-beta-D-arabinosyl-4H-chromen-4-one 0.05 mM, 49.4% inhibition 66579 3.4.22.69 2-(3',4'-dihydroxyphenyl)-5,7-dihydroxy-3-beta-D-galactosyl-4H-chromen-4-one 0.05 mM, 41.8% inhibition 66582 3.4.22.69 2-(3',4'-dihydroxyphenyl)-5,7-dihydroxy-3-beta-D-glucosyl-4H-chromen-4-one 0.05 mM, 57.5% inhibition 66580 3.4.22.69 2-(3',4'-dihydroxyphenyl)-5,7-dihydroxy-3-beta-L-fucosyl-4H-chromen-4-one 0.05 mM, 57.4% inhibition 66578 3.4.22.69 2-(3',4'-dihydroxyphenyl)-5-hydroxy-3,7-di(beta-D-galactosyl)-4H-chromen-4-one 0.05 mM, 53.0% inhibition 66581 3.4.22.69 2-(3-chlorophenyl)-2,2-difluoro-1-(furan-2-yl)ethanone 0.1 mM, 13% inhibition 147291 3.4.22.69 2-(3-chlorophenyl)-2-fluoro-1-(furan-2-yl)ethanone 0.1 mM, 15% inhibition 147290 3.4.22.69 2-(4,5-dihydro-1,3-thiazol-2-yl)-1-(1,3-thiazol-2-yl)ethanone - 65372 3.4.22.69 2-(4-aminophenyl)-6-methyl-1H-benzimidazole-7-sulfonic acid - 24838 3.4.22.69 2-(5-bromopyridin-3-yl)-1-(5-(4-chlorophenyl)furan-2-yl)-2-fluoroethanone - 72195 3.4.22.69 2-(5-bromopyridin-3-yl)-1-(5-(4-chlorophenyl)furan-2-yl)ethanone - 72194 3.4.22.69 2-(5-bromopyridin-3-yl)-1-[5-(4-chlorophenyl)furan-2-yl]ethanone - 200835 3.4.22.69 2-(5-bromopyridin-3-yl)-2,2-difluoro-1-(furan-2-yl)ethanone 0.1 mM, 21% inhibition 147292 3.4.22.69 2-(5-chloropyridin-3-yl)-2,2-difluoro-1-(furan-2-yl)ethanone 0.1 mM, 27% inhibition 147289 3.4.22.69 2-(5-chloropyridin-3-yl)-2-fluoro-1-(furan-2-yl)ethanone 0.1 mM, 14% inhibition 147288 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]acetamide - 261102 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0023 microM 261102 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]acetamide - 261103 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0029 microM 261103 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[4-(3-pyridyl)phenyl]acetamide - 261104 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[4-(3-pyridyl)phenyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0076 microM 261104 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[5-(1H-pyrazol-4-yl)-2-pyridyl]acetamide - 261105 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[5-(1H-pyrazol-4-yl)-2-pyridyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0019 microM 261105 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[6-(1H-pyrazol-4-yl)-3-pyridyl]acetamide - 261106 3.4.22.69 2-(benzotriazol-1-yl)-N-[(3-chlorophenyl)methyl]-N-[6-(1H-pyrazol-4-yl)-3-pyridyl]acetamide cytopathic effect inhibition assay, EC50 value 0.0038 microM 261106 3.4.22.69 2-(benzylsulfanyl)-4-(3-chlorophenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 79208 3.4.22.69 2-(benzylsulfanyl)-4-(4-methoxyphenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 79209 3.4.22.69 2-(benzylsulfanyl)-4-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 79161 3.4.22.69 2-(benzylsulfanyl)-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile - 79266 3.4.22.69 2-(N-(4-(tert-butyl)phenyl)vinylsulfonamido)-N-(3-chlorophenethyl)-2-(pyridin-3-yl)acetamide - 261117 3.4.22.69 2-(N-(4-(tert-butyl)phenyl)vinylsulfonamido)-N-(3-methoxyphenethyl)-2-(pyridin-3-yl)acetamide - 261118 3.4.22.69 2-(N-(4-(tert-butyl)phenyl)vinylsulfonamido)-N-(3-phenylpropyl)-2-(pyridin-3-yl)acetamide - 261119 3.4.22.69 2-(N-(4-(tert-butyl)phenyl)vinylsulfonamido)-N-(4-methoxyphenethyl)-2-(pyridin-3-yl)acetamide - 261120 3.4.22.69 2-(N-(4-(tert-butyl)phenyl)vinylsulfonamido)-N-cyclohexyl-2-(pyridin-3-yl)acetamide - 261121 3.4.22.69 2-([N-[(benzyloxy)carbonyl]-L-alanyl-L-valyl]amino)-5-[[(2S,5S)-5-[[(benzyloxy)carbonyl]amino]-2-(1-methylethyl)-4-oxohexanoyl]amino]-1,2,5,6-tetradeoxy-1,6-diphenyl-L-iditol - 65367 3.4.22.69 2-acetyl-3-(3-iodophenyl)-7-methoxy-3,3a,4,5-tetrahydro-2H-benzo[g]indazole - 70085 3.4.22.69 2-benzyl-2H-isoindole-4,7-dione - 70089 3.4.22.69 2-fluoro-2-(pyridin-3-yl)-1-(thiophen-2-yl)ethanone 0.1 mM, 10% inhibition 147286 3.4.22.69 2-methoxy-10a,11-dihydro-5aH-[1]benzofuro[3,2-b][1]benzopyran binding energy -96.2 kJ/mol, in-silico ADMET study displays excellent druggability and extremely low level of toxicity of the synthesized molecules 261161 3.4.22.69 2-methyl-10a,11-dihydro-5aH-[1]benzofuro[3,2-b][1]benzopyran binding energy -128.8 kJ/mol, in-silico ADMET study displays excellent druggability and extremely low level of toxicity of the synthesized molecules 261165 3.4.22.69 2-methylpropyl (4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)carbamate - 200850 3.4.22.69 2-methylpropyl [4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]carbamate - 200865 3.4.22.69 2-phenyl-5,7-dihydroxy-3-beta-D-galactosyl-4H-chromen-4-one 0.05 mM, 18.7% inhibition 139120 3.4.22.69 2-phenylethyl 2-methyl-4-(2-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate - 65426 3.4.22.69 2-[(1H-1,2,3-benzotriazol-1-yloxy)carbonyl]aniline inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65379 3.4.22.69 2-[(2-acetylphenyl)sulfonyl]benzoic acid - 65380 3.4.22.69 2-[(2-cyclohexylquinazolin-4-yl)sulfanyl]-N-(furan-2-ylmethyl)acetamide 0.01 mM, 30% inhibition 70066 3.4.22.69 2-[(4-chlorophenyl)disulfanyl]-1,3,4-oxadiazole reversible inhibition 236100 3.4.22.69 2-[(4-chlorophenyl)disulfanyl]pyrimidine reversible inhibition 236101 3.4.22.69 2-[(4-chlorophenyl)sulfonyl]-5-nitropyridine 1-oxide - 65381 3.4.22.69 2-[(4-nitrobenzyl)sulfanyl]-4-(3-nitrophenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 79246 3.4.22.69 2-[(4-nitrobenzyl)sulfanyl]-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitrile - 79248 3.4.22.69 2-[3-[(2Z)-3-(2H-1,3-benzodioxol-5-yl)prop-2-enoyl]-3-hydroxy-2-oxo-2,3-dihydro-1H-indol-1-yl]acetamide - 261203 3.4.22.69 2-[4-(chloroacetyl)-2-oxo-1,2,5,6-tetrahydropyridin-3-yl]-N-(3-chlorophenyl)acetamide - 261208 3.4.22.69 3,4',5,7,8-pentahydroxyflavone i.e. herbacetin, efficiently blocks the enzymatic activity, suggested to be a template to design functionally improved inhibitors 239907 3.4.22.69 3,4-dichloro-5-[2-(5-chloro-3-methyl-1-benzothien-2-yl)-2-oxoethyl]furan-2(5H)-one - 24851 3.4.22.69 3,4-dichloro-5-[2-(5-chloro-3-methyl-1-benzothiophen-2-yl)-2-oxoethyl]furan-2(5H)-one - 65429 3.4.22.69 3-(4-bromophenyl)-5-(4-chlorophenyl)-1-(3,4-dichlorophenyl)-4-(1H-imidazol-1-yl)-4,5-dihydro-1H-pyrazole - 70101 3.4.22.69 3-(N-L-gamma-Glu-L-Ala)-1,1,1-trifluoropropan-2-one - 71685 3.4.22.69 3-benzyl-1-[(6,7-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)methyl]-1-[2-(2-methylphenyl)ethyl]urea - 200889 3.4.22.69 3-benzyl-1-[(6,7-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl]-1-[2-(2-methylphenyl)ethyl]urea 0.01 mM, 40% inhibition 70129 3.4.22.69 3-[(2-furylmethyl)amino]-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-2-benzothiophene-1-carbonitrile - 65440 3.4.22.69 3-[1-(4-benzyloxyphenyl)-1H-tetrazol-5-ylthio]-4-hydroxyquinolin-2-(1H)one - 86698 3.4.22.69 3-[1-(4-benzyloxyphenyl)-1H-tetrazol-5-ylthio]-4-methoxyquinolin-2-(1H)one - 86694 3.4.22.69 3-[1-(4-ethoxyphenyl)-1H-tetrazol-5-ylthio]-4-hydroxyquinolin-2-(1H)one - 86699 3.4.22.69 3-[N-(N-benzyloxycarbonyl-L-Leu)]-4-phenyl-1,1,1-trifluorobutan-2-one - 71682 3.4.22.69 3-[N-(N-benzyloxycarbonyl-L-Phe)]-4-phenyl-1,1,1-trifluorobutan-2-one - 71683 3.4.22.69 3-[N-(N-tert-butoxycarbonyl)-L-Leu]-1,1,1-trifluorobutan-2-one - 71684 3.4.22.69 3-[N-[N-benzyloxycarbonyl-L-Ala-L-Val-L-Leu]]-4-phenyl-1,1,1-trifluorobutan-2-one - 71687 3.4.22.69 3-[N-[N-decanoyl-L-Leu]]-4-phenyl-1,1,1-trifluorobutan-2-one - 71686 3.4.22.69 3-{N-[N-tert-butoxycarbonyl-L-gamma-Glu(OtBu)-L-Ala]}-1,1,1-trifluoropropan-2-one - 147293 3.4.22.69 4,5-anhydro-2-([N-[(benzyloxy)carbonyl]-L-phenylalanyl]amino)-1,2-dideoxy-D-erythro-pent-3-ulose - 70145 3.4.22.69 4,6-dimethyl-2-[(4-methylphenyl)sulfonyl]-5-nitronicotinonitrile - 65473 3.4.22.69 4,6-dimethyl-5-nitro-2-(phenylsulfonyl)nicotinonitrile - 65474 3.4.22.69 4-((S)-2-((2S,3S)-2-((S)-2-acetamido-3-methylbutanamido)-3-(benzyloxy)butanamido)-4-methylpentanamido)-N,N-dimethyl-6-(5-nitro-1,4-dioxo-3,4-dihydrophthalazin-2(1H)-yl)-5-oxohexanamide - 200875 3.4.22.69 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide interacts with allosteric site II, binding free energy -18.4 kcal/mol, shows antiviral activity 261402 3.4.22.69 4-(3-nitrophenyl)-6-oxo-2-[(2-phenylethyl)sulfanyl]-1,6-dihydropyrimidine-5-carbonitrile - 78831 3.4.22.69 4-(4-chlorophenyl)-2-[(4-nitrobenzyl)sulfanyl]-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 78922 3.4.22.69 4-(4-chlorophenyl)-6-oxo-2-[(2-phenylethyl)sulfanyl]-1,6-dihydropyrimidine-5-carbonitrile - 79277 3.4.22.69 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide interacts with substrate-bindung site, binding free energy -22.16 kcal/mol, shows antiviral activity 261424 3.4.22.69 4-(4-methoxyphenyl)-2-[(4-nitrobenzyl)sulfanyl]-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 78919 3.4.22.69 4-(4-methoxyphenyl)-6-oxo-2-[(2-phenylethyl)sulfanyl]-1,6-dihydropyrimidine-5-carbonitrile - 78920 3.4.22.69 4-(4-methylphenyl)-2-[(4-nitrobenzyl)sulfanyl]-6-oxo-1,6-dihydropyrimidine-5-carbonitrile - 78921 3.4.22.69 4-(4-methylphenyl)-6-oxo-2-[(2-phenylethyl)sulfanyl]-1,6-dihydropyrimidine-5-carbonitrile - 79295 3.4.22.69 4-(5-chloro-2-thienyl)-2-[(2-thienylsulfonyl)methyl]-1,3-thiazole - 65506 3.4.22.69 4-([[4-cyclohexyl-5-(naphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl]methyl)-1,3-thiazol-2-amine competitive inhibitor, 58.23% inhibition at 0.1 mM 86674 3.4.22.69 4-benzyloxy-3-[1-(4-benzyloxyphenyl)-1H-tetrazol-5-ylthio]quinolin-2-(1H)one - 86697 3.4.22.69 4-benzyloxy-3-[1-(4-ethoxyphenyl)-1H-tetrazol-5-ylthio]quinolin-2-(1H)one - 86695 3.4.22.69 4-benzyloxy-3-[1-(4-methoxyphenyl)-1H-tetrazol-5-ylthio]quinolin-2-(1H)one - 86696 3.4.22.69 4-hydroxy-3-[1-(4-hydroxyphenyl)-1H-tetrazol-5-ylthio]quinolin-2-(1H)one - 86701 3.4.22.69 4-hydroxy-3-[1-(4-methoxyphenyl)-1H-tetrazol-5-ylthio]quinolin-2-(1H)one - 86700 3.4.22.69 4-methoxy-6-[([1,3]thiazolo[5,4-b]pyridin-2-ylsulfinyl)methyl]-2H-pyran-2-one - 70180 3.4.22.69 4-[(1H-1,2,3-benzotriazol-1-yloxy)carbonyl]-N,N-diethylaniline inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65511 3.4.22.69 4-[(1H-1,2,3-benzotriazol-1-yloxy)carbonyl]-N,N-dimethylaniline inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65512 3.4.22.69 4-[(1H-1,2,3-benzotriazol-1-yloxy)carbonyl]-N-methylaniline inhibition and irreversible mechanism-based inactivators, no irreversible inactivation with the C145A mutant enzyme 65513 3.4.22.69 4-[(1H-benzotriazol-1-yloxy)carbonyl]-N,N-diethylaniline - 200833 3.4.22.69 4-[(1S,2R)-2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol interacts with allosteric site I, binding free energy -12.8 kcal/mol, shows antiviral activity 261495 3.4.22.69 4-[(2,4-dimethyl-1,3-thiazol-5-yl)carbonyl]-3-hydroxy-1-[3-(morpholin-4-yl)propyl]-5-(3-nitrophenyl)-1,5-dihydro-2H-pyrrol-2-one competitive inhibitor, 49.14% inhibition at 0.1 mM 86676 3.4.22.69 4-[(3,5-dibromo-4-hydroxyphenyl)sulfonyl]benzoic acid - 65517 3.4.22.69 4-[(E)-[(2-methoxyphenyl)imino]methyl]-2-phenyl-1,3-oxazol-5-yl acetate - 70151 3.4.22.69 4-[(Z)-[1-(4-fluorophenyl)-5-oxo-3-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene]methyl]benzoic acid - 200888 3.4.22.69 4-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-3-phenyl-propionylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester - 66574 3.4.22.69 4-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester - 66575 3.4.22.69 4-[2-(2-benzyloxycarbonylamino-3-tert-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester - 66576 3.4.22.69 4-[[(4Z)-1-(3-chlorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl]benzoic acid binding free energy-160.63 kJ/mol, compound shows favorable pharmacokinetic and drug-like properties 261511 3.4.22.69 4-[[(4Z)-1-(4-chlorophenyl)-5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl]benzoic acid binding free energy-159.59 kJ/mol, compound shows favorable pharmacokinetic and drug-like properties 261512 3.4.22.69 4-[[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl]benzoic acid binding free energy -178.83 kJ/mol, compound shows favorable pharmacokinetic and drug-like properties 261513 3.4.22.69 5,7-dichloro-4-hydroxy-3-[1-(4-methoxy-phenyl)-1H-tetrazol-5-ylsulfanyl]-1H-quinolin-2-one - 86702 3.4.22.69 5,7-dichloro-4-hydroxy-3-[[1-(4-hydroxyphenyl)-1H-tetrazol-5-yl]sulfanyl]quinolin-2(1H)-one - 25639 3.4.22.69 5,7-dihydroxy 4',6-dimethoxyflavone 7-rutinoside i.e. pectolinarin, efficiently blocks the enzymatic activity, suggested to be a template to design functionally improved inhibitors 239909 3.4.22.69 5-(1,3-dimethyl-1H-pyrazol-5-yl)-N-(3-methyl-4-nitroisoxazol-5-yl)thiophene-2-carboxamide - 65569 3.4.22.69 5-(4-methylpiperidine-1-sulfonyl)-1-phenyl-1H-indole-2,3-dione - 239268 3.4.22.69 5-(4-methylpiperidine-1-sulfonyl)-1H-indole-2,3-dione - 239269 3.4.22.69 5-amino-1-[2-(1-benzothiophen-2-yl)-2-oxoethyl]-2,3-dihydro-1H-indole-2,3-dione binding free energy -169.15 kJ/mol, compound shows favorable pharmacokinetic and drug-like properties 261557 3.4.22.69 5-bromo-2-[(2Z)-2-[5-cyano-1-(3-hydroxypropyl)-4-methyl-2,6-dioxo-1,6-dihydropyridin-3(2H)-ylidene]hydrazinyl]benzoic acid - 261563 3.4.22.69 5-bromopyridin-3-yl thiophene-2-carboxylate - 200831 3.4.22.69 5-chloropyridin-3-yl (3S)-2-acetyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate - 70192 3.4.22.69 5-chloropyridin-3-yl 1-acetyl-1H-indole-4-carboxylate - 70195 3.4.22.69 5-chloropyridin-3-yl 1-acetyl-1H-indole-5-carboxylate - 70196 3.4.22.69 5-chloropyridin-3-yl 1-naphthoate - 36889 3.4.22.69 5-chloropyridin-3-yl 1-[(3-nitrophenyl)sulfonyl]-1H-indole-5-carboxylate - 70193 3.4.22.69 5-chloropyridin-3-yl 1-[(4-methylphenyl)sulfonyl]-1H-indole-5-carboxylate - 70194 3.4.22.69 5-chloropyridin-3-yl 1H-indole-2-carboxylate - 150568 3.4.22.69 5-chloropyridin-3-yl 1H-indole-4-carboxylate - 70197 3.4.22.69 5-chloropyridin-3-yl 1H-indole-5-carboxylate - 38088 3.4.22.69 5-chloropyridin-3-yl 1H-indole-6-carboxylate - 70198 3.4.22.69 5-chloropyridin-3-yl 1H-indole-7-carboxylate - 70199 3.4.22.69 5-chloropyridin-3-yl 2-nitrobenzoate - 36890 3.4.22.69 5-chloropyridin-3-yl 2-oxo-2H-chromene-3-carboxylate - 36891 3.4.22.69 5-chloropyridin-3-yl 3-nitrobenzoate - 65589 3.4.22.69 5-chloropyridin-3-yl 4-chlorobenzoate - 65590 3.4.22.69 5-chloropyridin-3-yl 5-(2-nitrophenyl)-2-furoate - 65591 3.4.22.69 5-chloropyridin-3-yl 5-(3-nitrophenyl)-2-furoate - 65592 3.4.22.69 5-chloropyridin-3-yl 5-(4-chloro-2-nitrophenyl)-2-furoate - 65593 3.4.22.69 5-chloropyridin-3-yl 5-(4-chlorophenyl)-2-furoate - 65594 3.4.22.69 5-chloropyridin-3-yl 5-(4-nitrophenyl)-2-furoate - 65595 3.4.22.69 5-chloropyridin-3-yl isonicotinate - 36892 3.4.22.69 5-chloropyridin-3-yl nicotinate - 65596 3.4.22.69 5-chloropyridin-3-yl thiophene-2-carboxylate - 10038 3.4.22.69 5-[(4-chlorophenyl)sulfonyl]pyrimidine-2,4-diamine - 65580 3.4.22.69 6-oxo-4-phenyl-2-[(2-phenylethyl)sulfanyl]-1,6-dihydropyrimidine-5-carbonitrile - 79014 3.4.22.69 acetyl-Ala-Val-Leu-NHCH(CH2CH2CON(CH3)2)-CHO - 71689 3.4.22.69 acetyl-leucylalanyl-alanyl-ketomethyl(cycloglutamine)-phthalhydrazide - 139118 3.4.22.69 acetyl-Ser-Ala-Val-Leu-NHCH(CH2CH2CON(CH3)2)-CHO - 71690 3.4.22.69 acetyl-Thr-Ser-Ala-Val-Leu-NHCH(CH2CH2CON(CH3)2)-CHO - 71691 3.4.22.69 acetyl-Val-Leu-NHCH(CH2CH2CON(CH3)2)-CHO - 71688 3.4.22.69 acetyl-valyl-(O-benzyloxy)threonyl-leucyl-ketomethyl(cycloglutamine)-phthalhydrazide - 139117 3.4.22.69 amentoflavone binding affinity -9.4 kcal/mol, ligand induces conformational changes in the protein with decreased surface area and higher stability. Compound possess promising druglikeness properties 4391 3.4.22.69 apigenin-7-O-rhamnoglucoside i.e. rhoifolin, efficiently blocks the enzymatic activity, suggested to be a template to design functionally improved inhibitors 239908 3.4.22.69 benzoyl-YYNQ-H - 239910 3.4.22.69 benzyl ((2S,3R)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)carbamate - 200895 3.4.22.69 benzyl ((S)-1-(((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate - 200879 3.4.22.69 benzyl ((S)-1-(((S)-1-(5-(2-methoxyphenyl)thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate - 200915 3.4.22.69 benzyl ((S)-1-(((S)-1-(5-(4-methoxyphenyl)thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate - 200914 3.4.22.69 benzyl ((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate - 200897 3.4.22.69 benzyl ((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-1-oxohexan-2-yl)carbamate - 200893 3.4.22.69 benzyl ((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate - 200894 3.4.22.69 benzyl ((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-(methylthio)-1-oxobutan-2-yl)carbamate - 200896 3.4.22.69 benzyl ((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate - 200892 3.4.22.69 benzyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)-1-(5-(p-tolyl)thiazol-2-yl)propan-2-yl)amino)pentan-2-yl)carbamate - 200913 3.4.22.69 benzyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)-1-(5-phenylthiazol-2-yl)propan-2-yl)amino)pentan-2-yl)carbamate - 200912 3.4.22.69 benzyl (2S,3S)-3-tert-butoxy-1-((S)-3-cyclohexyl-1-oxo-1-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-ylamino)propan-2-ylamino)-1-oxobutan-2-ylcarbamate - 36895 3.4.22.69 benzyl [(1S)-1-benzyl-3-chloro-2-oxopropyl]carbamate potent and selective inhibitor 70268 3.4.22.69 benzyl [(1S)-3-chloro-1-(4-fluorobenzyl)-2-oxopropyl]carbamate potent and selective inhibitor 70269 3.4.22.69 benzyl [(1S)-3-chloro-1-(naphthalen-2-ylmethyl)-2-oxopropyl]carbamate potent and selective inhibitor 70270 3.4.22.69 benzyl [(1S,4S,7S,8R,9R,10S,13S,16S)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate - 65702 3.4.22.69 benzyl [(2R)-4-[(5,8-dihydronaphthalene-1-carbonyl)amino]-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]carbamate compound can effectively occupy both the main protease Mpro protein cavity and the PLpro protein cavity and form high frequency contacts with key amino acid residues (Mpro: His41, Cys145, Glu166, PLpro: Cys111) 261811 3.4.22.69 benzyl [(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diethylamino)-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate - 79006 3.4.22.69 benzyl [(2S)-1-[[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diethylamino)-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate - 79004 3.4.22.69 benzyl [(2S)-1-[[(2S)-1-[[(2S)-5-(diethylamino)-1,5-dioxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate - 79005 3.4.22.69 benzyl [(2S)-1-[[(2S)-5-(diethylamino)-1,5-dioxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate - 79228 3.4.22.69 benzyl [(2S)-1-[[(2S)-5-(diethylamino)-1,5-dioxo-1-(1,3-thiazol-2-yl)pentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate - 79001 3.4.22.69 benzyl [(2S)-3-(naphthalen-1-yl)-1-oxo-1-[2-[(3S)-2-oxopyrrolidin-3-yl]acetamido]propan-2-yl]carbamate compound can effectively occupy both the main protease Mpro protein cavity and the PLpro protein cavity and form high frequency contacts with key amino acid residues (Mpro: His41, Cys145, Glu166, PLpro: Cys111) 261812 3.4.22.69 benzyl [(7S,8R,9R,10S)-8,9-dihydroxy-7,10-bis(1H-indol-3-ylmethyl)-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate highly selective for the 3CL protease and that no inhibitionis observed against HIV protease at 0.1 mM 65703 3.4.22.69 benzyl [1-([(1S)-1-cyano-2-[(1S)-2-oxocyclopentyl]ethyl]amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl]carbamate compound can effectively occupy both the main protease Mpro protein cavity and the PLpro protein cavity and form high frequency contacts with key amino acid residues (Mpro: His41, Cys145, Glu166, PLpro: Cys111) 261813 3.4.22.69 betulinic acid competitive 3725 3.4.22.69 bisdemethoxycurcumin docking score -7.3 kcal/mol, forms hydrogen bonds with amino acid residues Lys290, Gly248, His235, Thr341, and Glu340 6260 3.4.22.69 bis[1,3]thiazolo[4,5-b:5',4'-e]pyridine-2,6-diamine - 24880 3.4.22.69 Bz-Ala-Val-Leu-Phe-trifluromethyl ketone - 200874 3.4.22.69 Bz-Val-Asn-Ser-Thr-Leu-Gln-CMK - 200873 3.4.22.69 celastrol competitive inhibitor 14703 3.4.22.69 cinanserin - 37030 3.4.22.69 curcumin - 696 3.4.22.69 curcumin forms hydrogen bonds with 3CLpro residues Gln192 and Arg188 696 3.4.22.69 demethoxycurcumin docking score -7.02 kcal/mol, forms hydrogen bonds with residue His163 13941 3.4.22.69 deoxyneocryptotanshinone binding affinity -6.6 kcal/mol, interacts with amino acid residue Gln 110 239956 3.4.22.69 diethyl (2E,2'E)-3,3'-[sulfonylbis(benzene-4,1-diylimino)]bis(2-cyanoprop-2-enoate) - 65716 3.4.22.69 dihydrocelastrol - 27265 3.4.22.69 dihydrotanshinone binding affinity -6.8 kcal/mol, interacts with amino acid residue Gln 110 19484 3.4.22.69 DTT 80% of enzyme activity inhibited in the presence of 2.5 mM DTT 177 3.4.22.69 ellagic acid occupies a binding mode at the active site of 3CLpro, with hydrogen bonds with residues Cys44, Asn142, His164 and Gln189, and it forms hydrophobic interactions with residues Asn142, Cys145, Met165 and Met166, and pi-pi stacking with His41 1279 3.4.22.69 epigallocatechin gallate displays hydrophobic interactions with 3CLpro residues Met49, Met165 and Gln189, and hydrogen bonds with residues Asp187 and Glu166 1234 3.4.22.69 esculetin-4-carboxylic acid ethyl ester a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata 66577 3.4.22.69 ethyl (2E)-4-[(N-[(2E)-3-[4-(dimethylamino)phenyl]prop-2-enoyl]-L-phenylalanyl)amino]-5-phenylpent-2-enoate - 65718 3.4.22.69 ethyl (2E,4S)-4-[[(2R,5S)-2-benzyl-6-methyl-5-[[(5-methylisoxazol-3-yl)carbonyl]amino]-4-oxoheptanoyl]amino]-5-[(3S)-3-methyl-2-oxopyrrolidin-3-yl]pent-2-enoate - 65719 3.4.22.69 ethyl (2E,4S)-4-[[(2R,5S)-5-[(N-tert-butyl-L-seryl)amino]-6-methyl-2-(3-methylbut-2-en-1-yl)-4-oxoheptanoyl]amino]-5-[(3S)-3-methyl-2-oxopyrrolidin-3-yl]pent-2-enoate - 65720 3.4.22.69 ethyl (2E,4S)-4-[[(2R,5S)-6-methyl-2-(3-methylbut-2-en-1-yl)-5-[[(5-methylisoxazol-3-yl)carbonyl]amino]-4-oxoheptanoyl]amino]-5-[(3S)-3-methyl-2-oxopyrrolidin-3-yl]pent-2-enoate - 65721 3.4.22.69 ethyl 3-((5S,8S)-2-(3-amino-3-oxopropyl)-5-benzyl-8-isobutyl-4,7,10-trioxo-12-phenyl-11-oxa-2,3,6,9-tetraazadodecan-1-oyl)oxirane-2-carboxylate - 200877 3.4.22.69 extracts of Rheum palmatum - 160160 3.4.22.69 gallocatechin gallate binding affinity -9.4 kcal/mol, ligand induces conformational changes in the protein with decreased surface area and higher stability. Compound possess promising druglikeness properties 6836 3.4.22.69 GC376 peptidomimetic antiviral drug. A single amino acid change of N25S, but not A252S or K260N, leads to a statistically significant increase in the IC50 value as compared to that of wild-typwe enzyme 239905 3.4.22.69 GC376 - 239905 3.4.22.69 Hexachlorophene - 2082 3.4.22.69 Hg2+ - 33 3.4.22.69 iguesterin competitive inhibitor 40208 3.4.22.69 kazinol-A good binding affinity 262540 3.4.22.69 lopinavir displays hydrogen bond interactions with residues Thr26, Thr24, and a glide score of -6.12 kcal/mol and glide energy of -51.77 kcal/mol 1430 3.4.22.69 methyl 3-([N-[(benzyloxy)carbonyl]-L-valyl]amino)-5-fluoro-4-oxopentanoate potent and selective inhibitor 70288 3.4.22.69 methyl 4-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate - 24890 3.4.22.69 ML300 enzyme bound with a ML300 analogue highlights a unique induced-fit reorganization of the S2-S4 binding pockets leading to the first submicromolar non-covalent 3CLpro inhibitors retaining a single amide bond 201850 3.4.22.69 ML300 - 201850 3.4.22.69 ML300 cytopathic effect inhibition assay, EC50 value 0.020 microM 201850 3.4.22.69 additional information molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro 2 3.4.22.69 additional information based on the X-ray structure of 3CLPro co-crystallized with a trans-alpha,beta-unsaturated ethyl ester, a set of QM/QM and QM/MM calculations are performed, yielding three models with increasingly higher the number of atoms. It is suggested 3CLPro inhibitors need small polar groups to decrease the energy barrier for alkylation reaction. The results can be useful for the development of new compounds against SARS 2 3.4.22.69 additional information extracts from Rheum palmatum have a high level of inhibitory activity against 3CL protease with IC50 of 0.01376 mg/ml and an inhibition rate of up to 96% 2 3.4.22.69 additional information not inhibited by N-acetyl-Ser-Ala-Val-Leu-NHCH(CH2CH2CON(CH3)2)-CH2CH-CHCOOEt and N-acetyl-Ser-Ala-Val-Leu-NHCH(CH2CH2CON(CH3)2)-(CH2)2-CH-CHCOOEt 2 3.4.22.69 additional information the low inhibition potencies of known covalently interacting inhibitors may, at least in part, be attributed to insufficient fostering of the proton-transfer reaction 2 3.4.22.69 additional information efforts to develop potent, non-covalent SARS-3CLpro inhibitors based upon a second chemical class of triazoles from our MLPCN screening campaign, detection of (benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamidophenyl carboxamides as enzyme inhibitors, noncovalent nanomolar inhibitors with an induced-fit binding, mechanism of action, overview. No inhibition by N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)benzamide, 2-methylpropyl (4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)carbamate, N-[4-(acetylamino)phenyl]-2-(1H-benzimidazol-1-yl)-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]acetamide, N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(2-methyl-1H-benzimidazol-1-yl)acetamide, N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(2-methyl-1H-imidazol-1-yl)acetamide, N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(1H-1,2,3-triazol-1-yl)acetamide, and N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamide 2 3.4.22.69 additional information design, synthesis, and biological evaluation of dipeptide-type enzyme inhibitors, docking and structure-activity relationship studie, overview 2 3.4.22.69 additional information development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds, design, synthesis, biological evaluation, and molecular docking studies, overview 2 3.4.22.69 additional information the fused ring structure of the decahydroisoquinolin functions as a scaffold for SARS 3CLpro inhibitors. Interactions take place at the S1 and S2 sites, as well as additional interactions at the N-substituent of the inhibitors 2 3.4.22.69 additional information curcumin derivatives with reliable ADME profile and high molecular binding potency as inhibitors of PLpro. High-affinity ligand-PLpro protein complexes involve residues Lys157, Glu161, Asp164, Arg166, Glu167, Met208, Pro247, Pro248, Tyr264, Tyr273 and Asp302 residues of PLpro 2 3.4.22.69 additional information molecular docking approach in conjugation with molecular dynamics simulations to find potential inhibitors of Mpro. N-substituted isatin derivatives and pyrazolone compounds can be used as a potent inhibitor and may possess an anti-viral activity against SARS-CoV-2 2 3.4.22.69 additional information identification of quercetin derivatives as inhibitors based on molecular docking and dynamics simulation studies 2 3.4.22.69 additional information the active ingredients in the oral mouth rinse products are not inhibitory: aloin A, aloin B, chlorhexidine, eucalyptol, hexetidine, menthol, triclosan, methyl salicylate, sodium fluoride and povidone 2 3.4.22.69 myricetin docking score -6.15 kcal/mol 484 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-1H-benzo[d]imidazole-2-carboxamide - 200951 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-1H-indole-2-carboxamide - 200940 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-1H-indole-3-carboxamide - 200955 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-1H-pyrrole-2-carboxamide - 200939 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-3-ethyl-5-methoxy-1H-indole-2-carboxamide - 200950 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-hydroxy-1H-indole-2-carboxamide - 200948 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-isobutoxy-1H-indole-2-carboxamide - 200947 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-isopropoxy-1H-indole-2-carboxamide - 200946 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methoxy-1H-indole-2-carboxamide - 200945 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-5-chloro-1H-indole-2-carboxamide - 200943 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-5-hydroxy-1H-indole-2-carboxamide - 200942 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-5-methoxy-1H-indole-2-carboxamide - 200941 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-5-methoxy-3-methyl-1H-indole-2-carboxamide - 200949 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-5-oxopyrrolidine-2-carboxamide - 200938 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-6-methoxy-1H-indole-2-carboxamide - 200944 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)benzofuran-2-carboxamide - 200954 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)benzo[d]thiazole-2-carboxamide - 200952 3.4.22.69 N-((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)indoline-2-carboxamide - 200953 3.4.22.69 N-(1-benzylpiperidin-4-yl)-2-(N-(4-(tert-butyl)phenyl)vinylsulfonamido)-2-(pyridin-3-yl)acetamide - 261930 3.4.22.69 N-(2,2'-bithien-5-ylmethyl)-1,3-dimethyl-4-nitro-1H-pyrazol-5-amine - 65811 3.4.22.69 N-(2-allylthiophenyl)cinnamide - 71675 3.4.22.69 N-(2-benzylthiophenyl)cinnamide - 71676 3.4.22.69 N-(2-carbomethoxyethylthiophenyl)cinnamide - 71677 3.4.22.69 N-(2-chloro-4-nitrophenyl)-Nalpha-[[4-(dimethylamino)phenyl]carbonyl]phenylalaninamide - 18434 3.4.22.69 N-(2-cinnamoylthiophenyl)cinnamide - 71680 3.4.22.69 N-(2-[2-[(2S)-1-cyclohexyl-3-oxopropan-2-yl]hydrazinyl]-4-methylpentanoyl)valyl-N-(1-hydroxy-3,4-dioxopentan-2-yl)alaninamide - 86692 3.4.22.69 N-(2-[2-[(2S)-3,3-dimethyl-1-oxobutan-2-yl]hydrazinyl]-4-methylpentanoyl)valyl-N-(1-hydroxy-3,4-dioxopentan-2-yl)alaninamide - 86690 3.4.22.69 N-(2-[[3-(dimethylamino)propyl]sulfanyl]phenyl)-3-phenylpropanamide - 200883 3.4.22.69 N-(3-methoxyphenyl)glycyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-L-leucinamide - 200937 3.4.22.69 N-(4-(tert-butyl)phenyl)-2-chloro-N-(2-(cyclohexylamino)-1-(5-methylpyrazin-2-yl)-2-oxoethyl)acetamide - 261942 3.4.22.69 N-(4-(tert-butyl)phenyl)-2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl) acetamide - 261943 3.4.22.69 N-(4-(tert-butyl)phenyl)-2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(pyridin-4-yl)ethyl)acetamide - 261944 3.4.22.69 N-(4-(tert-butyl)phenyl)-2-chloro-N-(2-(cyclopentylamino)-2-oxo-1-(pyridin-3-yl)ethyl)acetamide - 261945 3.4.22.69 N-(4-(tert-butyl)phenyl)-N-(2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl)-4-hydroxybut-2-ynamide - 261946 3.4.22.69 N-(4-aminophenyl)-2-(1H-benzotriazol-1-yl)-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]acetamide - 200838 3.4.22.69 N-(4-methyl-2-[2-[(2S)-1-oxo-3-(thiophen-2-yl)propan-2-yl]hydrazinyl]pentanoyl)valyl-N-(1-hydroxy-3,4-dioxopentan-2-yl)alaninamide - 86693 3.4.22.69 N-(4-methyl-2-[2-[(2S)-1-oxo-3-phenylpropan-2-yl]hydrazinyl]pentanoyl)valyl-N-(1-hydroxy-3,4-dioxopentan-2-yl)alaninamide - 86691 3.4.22.69 N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-1H-imidazole-4-carboxamide compound shows a broad spectrum of anti-viral activities. Water molecules enter the free binding S regions and weaken protein-inhibitor fundamental interactions gradually. N142, G143, and H163 are the essential residues, which cause key protein-ligand interactions 262531 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)-1,2-oxazole-5-carboxamide - 200849 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)-2,2-dimethylpropanamide - 200843 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)-2-methylpropanamide - 200842 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)benzamide - 200847 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)cyclobutanecarboxamide - 200845 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)cyclohexanecarboxamide - 200846 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)cyclopropanecarboxamide - 200844 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)propanamide - 200841 3.4.22.69 N-(4-[(1H-benzotriazol-1-ylacetyl)[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]amino]phenyl)thiophene-2-carboxamide - 200848 3.4.22.69 N-(4-[[(4Z)-5-oxo-1,3-diphenyl-4,5-dihydro-1H-pyrazol-4-ylidene]methyl]phenyl)acetamide binding free energy -225.01 kJ/mol, compound shows favorable pharmacokinetic and drug-like properties 261962 3.4.22.69 N-(5-benzoyl-4-phenyl-1,3-thiazol-2-yl)-2-(4-ethylsulfonylphenyl)acetamide binding energy -59.6 kJ/mol 262533 3.4.22.69 N-(furan-2-ylmethyl)-2-[[5-(morpholin-4-yl)-1,2,3,4-tetrahydropyrimido[4',5':4,5]thieno[2,3-c]isoquinolin-8-yl]sulfanyl]acetamide competitive inhibitor, 53.27% inhibition at 0.1 mM 86678 3.4.22.69 N-acetyl-Ala-Val-Cha-His - 86686 3.4.22.69 N-acetyl-Asn-Val-Cha-His - 86687 3.4.22.69 N-acetyl-DSFDQ micromolar inhibitor 86671 3.4.22.69 N-acetyl-ESTLQ micromolar inhibitor 86669 3.4.22.69 N-acetyl-L-threonyl-N-[(3R,4S,4aR,8aS)-2-(4-bromobenzoyl)-3-([[(2S)-1-(1H-imidazol-4-yl)-3-oxopropan-2-yl]amino]methyl)decahydroisoquinolin-4-yl]glycinamide - 239911 3.4.22.69 N-acetyl-L-threonyl-N-[(3R,4S,4aR,8aS)-3-([[(2S)-1,1-bis(ethylsulfanyl)-3-(1H-imidazol-4-yl)propan-2-yl]amino]methyl)-2-(4-bromobenzoyl)decahydroisoquinolin-4-yl]glycinamide - 239267 3.4.22.69 N-acetyl-NSFSQ micromolar inhibitor 86670 3.4.22.69 N-acetyl-NSTSQ micromolar inhibitor 86672 3.4.22.69 N-acetyl-Ser-Ala-Val-Cha-His - 86685 3.4.22.69 N-acetyl-Ser-Ala-Val-Leu-His - 86683 3.4.22.69 N-acetyl-Ser-Ala-Val-Leu-NHCH(CH2CH2CON(CH3)2)-CH=CHCOOEt - 86682 3.4.22.69 N-acetyl-Ser-Ala-Val-Leu-NHCH-(CH2CH2CON(CH3)2)-CHO - 86681 3.4.22.69 N-acetyl-Ser-Ala-Val-Leu-NHCH[CH2CH2CON(CH3)2]CH2CH2CH=CHCOOC2H5 - 167912 3.4.22.69 N-acetyl-Ser-Ala-Val-Phe-His - 86684 3.4.22.69 N-acetyl-Ser-Val-Cha-His - 86688 3.4.22.69 N-acetyl-Thr-Val-Cha-His - 86689 3.4.22.69 N-benzyl-2-(N-(4-(tert-butyl)phenyl)-2-chloroacetamido)-2-(pyridin-3-yl)acetamide - 261987 3.4.22.69 N-ethyl-N-phenyldithiocarbamic acid zinc - 66570 3.4.22.69 N-tert-butyl-2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetamide - 200882 3.4.22.69 N-tert-butyl-L-seryl-L-valyl-N-[(1S,2E)-4-ethoxy-1-[[(3S)-3-methyl-2-oxopyrrolidin-3-yl]methyl]-4-oxobut-2-en-1-yl]-L-phenylalaninamide - 65951 3.4.22.69 N-tert-butyl-L-seryl-L-valyl-N-[(1S,2E)-4-ethoxy-4-oxo-1-[2-(2-oxopyrrolidin-3-yl)ethyl]but-2-en-1-yl]-L-leucinamide - 65952 3.4.22.69 N-[(1E)-3-[(2E)-2-(4-hydroxy-3,5-dimethoxybenzylidene)hydrazinyl]-3-oxo-1-phenylprop-1-en-2-yl]benzamide competitive inhibitor, 56.11% inhibition at 0.1 mM 86677 3.4.22.69 N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide - 200836 3.4.22.69 N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide noncovalent inhibitor, evaluation of unbinding pathways 200836 3.4.22.69 N-[(1Z)-3-[[3-(dimethylamino)propyl]amino]-1-[5-(2-nitrophenyl)furan-2-yl]-3-oxoprop-1-en-2-yl]-4-methylbenzamide competitive inhibitor, 81.43% inhibition at 0.1 mM 86680 3.4.22.69 N-[(1Z)-3-[[3-(dimethylamino)propyl]amino]-1-[5-(3-nitrophenyl)furan-2-yl]-3-oxoprop-1-en-2-yl]-4-methylbenzamide competitive inhibitor, 82.59% inhibition at 0.1 mM 86679 3.4.22.69 N-[(2S)-1-oxo-3-phenylpropan-2-yl]-Na-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide - 86673 3.4.22.69 N-[(5-methyl-4,5-dihydro-1H-pyrazol-3-yl)carbonyl]-L-valyl-N-[(1S,2E)-4-ethoxy-1-[[(3S)-3-methyl-2-oxopyrrolidin-3-yl]methyl]-4-oxobut-2-en-1-yl]-L-leucinamide - 65903 3.4.22.69 N-[(5-methyl-4,5-dihydro-1H-pyrazol-3-yl)carbonyl]-L-valyl-N-[(1S,2E)-4-ethoxy-1-[[(3S)-3-methyl-2-oxopyrrolidin-3-yl]methyl]-4-oxobut-2-en-1-yl]-L-phenylalaninamide - 65904 3.4.22.69 N-[(benzyloxy)carbonyl]-3-[(2,2-dimethylpropanoyl)amino]-L-alanyl-N-[(1S,2E)-4-oxo-1-[[(3S)-2-oxopyrrolidin-3-yl]methyl]pent-2-en-1-yl]-L-leucinamide inhibits the viral protease, thus preventing CVB3 genome replication 70341 3.4.22.69 N-[(benzyloxy)carbonyl]-L-alanyl-L-valyl-N-[(3S)-6-(dipropylamino)-1,1,1-trifluoro-2,6-dioxohexan-3-yl]-L-leucinamide - 79280 3.4.22.69 N-[(benzyloxy)carbonyl]-L-alanyl-L-valyl-N-[(3S)-6-amino-1,1,1-trifluoro-2,6-dioxohexan-3-yl]-L-leucinamide - 78987 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(2S)-1,5-dioxo-1,5-di(1,3-thiazol-2-yl)pentan-2-yl]-L-leucinamide - 78988 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-L-leucinamide - 200935 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]-L-leucinamide - 78986 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(2S)-5-(morpholin-4-yl)-1,5-dioxo-1-(1,3-thiazol-2-yl)pentan-2-yl]-L-leucinamide - 78964 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(3S)-1,1,1-trifluoro-6-(morpholin-4-yl)-2,6-dioxohexan-3-yl]-L-leucinamide - 78978 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(3S)-5-carboxy-1,1,1-trifluoro-2-oxopentan-3-yl]-L-leucinamide - 78980 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(3S)-6-(dipropylamino)-1,1,1-trifluoro-2,6-dioxohexan-3-yl]-L-leucinamide - 78981 3.4.22.69 N-[(benzyloxy)carbonyl]-L-valyl-N-[(3S)-6-[benzyl(methyl)amino]-1,1,1-trifluoro-2,6-dioxohexan-3-yl]-L-leucinamide - 79041 3.4.22.69 N-[(benzyloxy)carbonyl]-O-tert-butylthreonyl-N-[(1S)-1-formyl-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-L-phenylalaninamide inhibits the viral protease, thus preventing CVB3 genome replication 70342 3.4.22.69 N-[(benzyloxy)carbonyl]-O-tert-butylthreonyl-N-[(1S,2E)-4-cyclopropyl-4-oxo-1-[[(3S)-2-oxopyrrolidin-3-yl]methyl]but-2-en-1-yl]-L-leucinamide - 70343 3.4.22.69 N-[(benzyloxy)carbonyl]-O-tert-butylthreonyl-N-[(1S,2E)-4-ethoxy-4-oxo-1-[[(3S)-2-oxopyrrolidin-3-yl]methyl]but-2-en-1-yl]-L-leucinamide - 70344 3.4.22.69 N-[2-(2-cyanocinnamoylthio)phenyl]-2-cyanocinnamide - 71681 3.4.22.69 N-[2-(2-pyridylmethylthio)phenyl]cinnamide - 71678 3.4.22.69 N-[2-(3-dimethylaminopropylthio)phenyl]-2-cyanocinnamide - 71674 3.4.22.69 N-[2-(3-pyridylmethylthio)phenyl]cinnamide - 71679 3.4.22.69 N-[3-(5-tert-butyl-2-methyl-3-furyl)-1H-pyrazol-5-yl]thiophene-2-sulfonamide - 65934 3.4.22.69 N-[4-(1H-imidazol-4-yl)phenyl]-2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)acetamide - 262019 3.4.22.69 N-[4-(1H-imidazol-4-yl)phenyl]-2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)acetamide cytopathic effect inhibition assay, EC50 value 0.0005 microM 262019 3.4.22.69 N-[4-(1H-pyrazol-4-yl)phenyl]-2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)acetamide - 262020 3.4.22.69 N-[4-(1H-pyrazol-4-yl)phenyl]-2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(3-chlorobenzyl)acetamide cytopathic effect inhibition assay, EC50 value 0.0012 microM 262020 3.4.22.69 N-[4-(2-acetylpyridin-3-yl)phenyl]-2-(1H-benzotriazol-1-yl)-N-(thiophen-3-ylmethyl)acetamide - 200870 3.4.22.69 N-[4-(2-acetylpyrimidin-5-yl)phenyl]-2-(1H-benzotriazol-1-yl)-N-(thiophen-3-ylmethyl)acetamide - 200872 3.4.22.69 N-[4-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzyl]-1-ethyl-1H-benzimidazol-2-amine - 70365 3.4.22.69 N-[4-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzyl]-1-propyl-1H-benzimidazol-2-amine - 70366 3.4.22.69 N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)butanamide interacts with allosteric site I, binding free energy -19.9 kcal/mol, shows antiviral activity 262028 3.4.22.69 N-[4-(acetylamino)phenyl]-2-(1H-benzimidazol-1-yl)-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]acetamide - 200859 3.4.22.69 N-[4-(acetylamino)phenyl]-2-(1H-benzotriazol-1-yl)-N-[(1R)-2-[(2-methylbutan-2-yl)amino]-1-(1-methyl-1H-pyrrol-2-yl)-2-oxoethyl]acetamide noncovalent inhibitor, evalutation of unbinding pathways, Met49 and Gln189 are important residues for interactions 262530 3.4.22.69 N-[4-(acetylamino)phenyl]-2-(1H-benzotriazol-1-yl)-N-[(1R)-2-[(2-methylbutan-2-yl)amino]-1-(1-methyl-1H-pyrrol-3-yl)-2-oxoethyl]acetamide - 200837 3.4.22.69 N-[4-(acetylamino)phenyl]-2-(1H-benzotriazol-1-yl)-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]acetamide - 200839 3.4.22.69 N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(1H-1,2,3-triazol-1-yl)acetamide - 200862 3.4.22.69 N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(2-methyl-1H-benzimidazol-1-yl)acetamide - 200860 3.4.22.69 N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(2-methyl-1H-imidazol-1-yl)acetamide - 200861 3.4.22.69 N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide - 200864 3.4.22.69 N-[4-(acetylamino)phenyl]-N-[2-(tert-butylamino)-2-oxo-1-(thiophen-3-yl)ethyl]-2-[4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl]acetamide - 200863 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]-2,2-dimethylpropanamide - 200853 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]-2-methylpropanamide - 200852 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]-3-methoxypropanamide - 200854 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]benzamide - 200858 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]cyclobutanecarboxamide - 200856 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]cyclohexanecarboxamide - 200857 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]cyclopropanecarboxamide - 200855 3.4.22.69 N-[4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl]propanamide - 200851 3.4.22.69 N-[4-[(4-chlorophenyl)sulfonyl]-3-(methylthio)-1H-pyrazol-5-yl]thiophene-2-carboxamide - 65942 3.4.22.69 N-[[3-(dimethylamino)phenoxy]acetyl]-L-valyl-N-[(2S)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-L-leucinamide - 200936 3.4.22.69 N2-[(benzyloxy)carbonyl]-N-[(3S)-6-(dipropylamino)-1,1,1-trifluoro-2,6-dioxohexan-3-yl]-L-leucinamide - 78852 3.4.22.69 NaCl 80% of enzyme activity inhibited in the presence of 100 mM NaCl 42 3.4.22.69 Nalpha-[(2E)-3-(4-chloro-2-fluorophenyl)prop-2-enoyl]-N-[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-D-phenylalaninamide - 239270 3.4.22.69 niclosamide - 37029 3.4.22.69 NP-40 80% of enzyme activity inhibited in the presence of 0.1% NP-40 6714 3.4.22.69 NPI52 - 239906 3.4.22.69 phenylmercuric acetate - 2497 3.4.22.69 Phenylmercuric nitrate - 9242 3.4.22.69 pristimerin competitive inhibitor 14952 3.4.22.69 quercetin - 137 3.4.22.69 quercetin docking score -6.58 kcal/mol, forms hydrogen bonds with residues Asn142, Gly143, Ser144, Leu141, Cys145, His41, and Thr26 137 3.4.22.69 quercetin-3-neohesperidoside-7-rhamnoside binding affinity -8.8 kcal/mol, aditionally binds to viral protease PLpro 262535 3.4.22.69 quercetin-3-[rhamnosyl-(1->2)-alpha-L-arabinopyranoside] binding affinity -8.8 kcal/mol, aditionally binds to viral protease PLpro 262534 3.4.22.69 raloxifene binding energy -66.1 kJ/mol 4142 3.4.22.69 remdesivir displays hydrogen bond interactions with residues Gln189, Thr26, Gly143, Glu166, and a glide score of -6.97 kcal/mol and glide energy of -55.35 kcal/mol 237593 3.4.22.69 remdesivir binding affinity -8.8 kcal/mol, binding free energy -241.4 kcal/mol 237593 3.4.22.69 remdesivir binding affinity -6.4 kcal/mol, aditionally binds to viral protease PLpro 237593 3.4.22.69 resveratrol shows labile interactions 799 3.4.22.69 ritonavir displays hydrogen bond interactions with residues Gly143, Asn142, Glu166, Gln189, and a glide score of -10.4 kcal/mol and glide energy of -7.3 kcal/mol 996 3.4.22.69 S-[5-(trichloromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate - 65974 3.4.22.69 savinin competitive 37028 3.4.22.69 savinin good binding affinity 37028 3.4.22.69 scutellarin docking score -7.13 kcal/mol, forms hydrogen bonds with residues Gly143 and His163 192193 3.4.22.69 sulfonyldi-4,1-phenylene bis(2,3,3-trichloroacrylate) - 65975 3.4.22.69 tafenoquine 8-aminoquinoline antimalarial drug, directly inhibits SARS-CoV-2 Mpro in vitro. Tafenoquine binding reduces the helical content but also induces local conformational changes in SARS-CoV-2 Mpro, resulting in resistance to trypsin digestion. Tafenoquine inhibits SARS-CoV-2 production in a cell culture system 262144 3.4.22.69 tanshinone A binding affinity -6.7 kcal/mol, interacts with amino acid residue Gln 110 262538 3.4.22.69 tanshinone B binding affinity -6.8 kcal/mol 262539 3.4.22.69 tanshinone C binding affinity -7.0 kcal/mol, interacts with amino acid residue Gln 110 262537 3.4.22.69 tert-butyl ((S)-1-(((S)-1-(benzo[d]thiazol-2-yl)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate - 200891 3.4.22.69 tert-butyl (3S)-3-[[(benzyloxy)carbonyl]amino]-5-bromo-4-oxopentanoate potent and selective inhibitor 70397 3.4.22.69 tert-butyl [1-[(2S)-1-([(2S)-4-(benzylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]amino)-3-cyclopropyl-1-oxopropan-2-yl]-2-oxo-1,2-dihydropyridin-3-yl]carbamate - 239262 3.4.22.69 tetraethyl 2,2'-[sulfonylbis(benzene-4,1-diyliminomethylylidene)]dipropanedioate - 66019 3.4.22.69 TG-0203770 - 40428 3.4.22.69 TG-0204998 - 40426 3.4.22.69 TG-0205221 - 40429 3.4.22.69 TG-0205486 - 40427 3.4.22.69 theaflavin-3,3-digallate good binding affinity 217300 3.4.22.69 thimerosal - 2762 3.4.22.69 tingenone competitive inhibitor 40430 3.4.22.69 toluene-3,4-dithiolato zinc - 66571 3.4.22.69 Val-Thr-Ala-Gln - 239914 3.4.22.69 Val-Thr-Leu-Gln tetrapeptide derived from the C-terminal portion of the enzyme, mutation of residue Phe in P2 position to Leu 239912 3.4.22.69 Val-Thr-Phe-Gln wild-type tetrapeptide derived from the C-terminal portion of the enzyme 239913 3.4.22.69 Z-Val-Leu-Ala(-pyrrolidone-3-yl)-2-benzothiazole - 201851 3.4.22.69 zinc N-ethyl-N-phenyldithiocarbamate - 81314 3.4.22.69 Zn2+ - 14 3.4.22.69 [3-([[3-(dihydroxyboranyl)benzyl]oxy]carbonyl)-5-nitrophenyl]boronic acid - 65281 3.4.22.69 [benzene-1,2-diylbis[methanediylcarbamoyl(5-nitrobenzene-3,1-diyl)]]diboronic acid - 65284 3.4.22.69 [benzene-1,2-diylbis[methanediyloxycarbonyl(5-nitrobenzene-3,1-diyl)]]diboronic acid - 65285 3.4.22.69 [benzene-1,3-diylbis[oxycarbonyl(5-nitrobenzene-3,1-diyl)]]diboronic acid - 65286 3.4.22.69 [benzene-1,4-diylbis[carbamoyl(5-nitrobenzene-3,1-diyl)]]diboronic acid - 65287 3.4.22.69 [benzene-1,4-diylbis[oxycarbonyl(5-nitrobenzene-3,1-diyl)]]diboronic acid - 65288